Schietzel, Simeon
Chocano-Bedoya, Patricia O.
Sadlon, Angelique
Gagesch, Michael
Willett, Walter C.
Orav, Endel J.
Kressig, Reto W.
Vellas, Bruno
Rizzoli, René
da Silva, José A. P.
Blauth, Michael
Kanis, John A.
Egli, Andreas
Bischoff-Ferrari, Heike A.
Article History
Received: 20 September 2021
Accepted: 22 December 2021
First Online: 2 March 2022
Declarations
:
: In our study we investigate baseline data of the DO-HEALTH trial. DO-HEALTH was approved by local/national ethics committee and regulatory authorities of all 5 countries (Switzerland, Germany, Austria, France, Portugal). For the coordinating centre of Do-HEALTH, the accredited ethics committee Cantonal Ethics Commission (CEC) Zurich, Switzerland, approved the trial. A project ethic committee provided ethical guidance to the consortium and ensured that the clinical trial was carried out within national and European regulations. DO-HEALTH was a Phase III trial (therapeutic confirmatory) and was conducted according to the ICH GCP Guidelines (CPMP/ICH/135/95). All participants gave their unpersuaded and full consent to participate in the trial.
: Not applicable.
: The authors declare that they have no competing interests.